Neurovascular Devices Market by Disease Pathology (Cerebral Ameurysm (Embolic coils), Ischemic Stroke (Clot retrievers, Aspiration, Microcatheters), AVM (Liquid Embolic Agents), End User (Hospitals), & Region - Global Forecast to 2028
The global neurovascular devices market is projected to reach USD 5.5 Billion by 2028 from USD 3.6 Billion in 2023, at a CAGR of 8.7% during the forecast period. The increase in the demand for neurovascular devices market is driven by the increasing population proportion at a risk of developing various neurovascular diseases such as Ischemic stroke, cerebral aneurysms owing to the growing prevalence of hypertension, diabetes, and obesity. However, high cost of neuro-interventional procedures and associated products and shortage of skilled neurologists across emerging countries are likely to hamper the growth of market.
“Ischemic stroke segment accounted for the highest CAGR during the forecast period”
Based on disease pathology, the neurovascular devices market is segmented into cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies (includes cavernous malformations and moyamoya disease). The ischemic stroke segment to grow a at a higher CAGR owing to increasing incidence of ischemic stroke and increase in the mechanical thrombectomy procedures.
“The Hospitals & surgical centers segment accounted for the largest market share in the neurovascular devices market, by end user, during the forecast period”
Based on end user, the neurovascular devices market is segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes. The hospital & surgical centers captured the largest share of neurovascular devices market during the forecast period attributed to the increasing hospitalization of target patient population, rising volume of neurovascular surgeries, and upgradation in the infrastructure of hospitals in developing nations along with the availability of technological advance neurovascular treatment devices in these settings.
“The North America segment accounted for the highest market share in the neurovascular devices market, by region, during the forecast period”
Based on the region, the global neurovascular devices market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to witness a high market share during the forecast period. This can be attributed to the factors such as strong adoption of endovascular treatment procedures for the ischemic stroke, cerebral aneurysm, and arteriovenous malformation, availability of R& D investments for development of novel neurovascular devices, strong foothold of key players in region, and favorable reimbursement policy for neurovascular treatment procedures.
Breakdown of supply-side primary interviews, by company type, designation, and region:
Research Coverage
This research report categorizes the neurovascular devices market by disease pathology (cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies), by end user (hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the neurovascular devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the neurovascular devices market. Competitive analysis of upcoming startups in the neurovascular devices market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neurovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“Ischemic stroke segment accounted for the highest CAGR during the forecast period”
Based on disease pathology, the neurovascular devices market is segmented into cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies (includes cavernous malformations and moyamoya disease). The ischemic stroke segment to grow a at a higher CAGR owing to increasing incidence of ischemic stroke and increase in the mechanical thrombectomy procedures.
“The Hospitals & surgical centers segment accounted for the largest market share in the neurovascular devices market, by end user, during the forecast period”
Based on end user, the neurovascular devices market is segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes. The hospital & surgical centers captured the largest share of neurovascular devices market during the forecast period attributed to the increasing hospitalization of target patient population, rising volume of neurovascular surgeries, and upgradation in the infrastructure of hospitals in developing nations along with the availability of technological advance neurovascular treatment devices in these settings.
“The North America segment accounted for the highest market share in the neurovascular devices market, by region, during the forecast period”
Based on the region, the global neurovascular devices market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to witness a high market share during the forecast period. This can be attributed to the factors such as strong adoption of endovascular treatment procedures for the ischemic stroke, cerebral aneurysm, and arteriovenous malformation, availability of R& D investments for development of novel neurovascular devices, strong foothold of key players in region, and favorable reimbursement policy for neurovascular treatment procedures.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (30%), Tier 2 (45%), and Tier 3 (25%)
- By Designation: C-level (20%), Director-level (20%), and Others (45%)
- By Region: North America (40%), Asia- Pacific (30%), Europe (20%), Latin America (7%) and Middle East & Africa(3%)
Research Coverage
This research report categorizes the neurovascular devices market by disease pathology (cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies), by end user (hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the neurovascular devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the neurovascular devices market. Competitive analysis of upcoming startups in the neurovascular devices market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neurovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (rising incidence of neurovascular diseases, increasing neurovascular procedures, availability of medical reimbursement, and expansion of healthcare infrastructure across emerging nations), restraints (high neurovascular procedural & related devices cost and shortage of skilled neurosurgeon in emerging countries ), opportunities (increase in the preference of minimally invasive neurosurgical procedures and rising R& D activities in neurovascular therapies), and challenges (stringent regulatory approval process for neurovascular treatment devices) influencing the growth of the neurovascular devices market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the neurovascular devices market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the neurovascular devices market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the neurovascular devices market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Stryker (US), Johnson & Johnson (US), Medtronic (Ireland), Terumo Corporation (Japan), Penumbra, Inc. (US), MicroPort Scientific Corporation (China), among others in the neurovascular devices market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 MARKET STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 NEUROVASCULAR DEVICES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 PRODUCT-BASED MARKET ESTIMATION
2.2.2 VOLUME-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: NEUROVASCULAR DEVICES MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
2.4.1 RESEARCH ASSUMPTIONS
2.4.2 RESEARCH LIMITATIONS
2.5 RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 7 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 8 HOSPITALS AND SURGICAL CENTERS SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD
4 PREMIUM INSIGHTS
4.1 NEUROVASCULAR DEVICES MARKET OVERVIEW
FIGURE 10 AN INCREASE IN THE NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS BRAIN/ CEREBRAL ANEURYSMS, STROKES, AND EPILEPSY, IS EXPECTED TO DRIVE THE MARKET GROWTH.
4.2 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 11 CEREBRAL ANEURYSMS TO DOMINATE NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD
4.3 NEUROVASCULAR DEVICES MARKET, BY REGION AND DISEASE PATHOLOGY (2022)
FIGURE 12 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE IN US
4.4 NEUROVASCULAR DEVICES MARKET, BY COUNTRY
FIGURE 13 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 14 NEUROVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of neurovascular diseases
FIGURE 15 PROPORTION OF GERIATRIC TO TOTAL WORLD POPULATION, BY COUNTRY, 2020 VS. 2030 (MILLION PEOPLE)
5.2.1.2 Availability of medical reimbursements for neurovascular procedures
TABLE 2 US: REIMBURSEMENT FOR INTERVENTIONAL NEUROLOGY PROCEDURES
5.2.1.3 Expansion of healthcare infrastructure across emerging economies
5.2.1.4 Rising demand for effective neurovascular therapies
5.2.2 RESTRAINTS
5.2.2.1 Shortage of skilled neurosurgeons
5.2.2.2 High procedural cost of neurovascular surgeries and associated products
5.2.3 OPPORTUNITIES
5.2.3.1 Rising R&D activities for neurovascular therapies
5.2.3.2 Growing preference for minimally invasive neurosurgical procedures
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory approval process for medical devices
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED THROUGH REGULATION & DISTRIBUTION STAGES
5.5 PORTER’S FIVE FORCES ANALYSIS
5.5.1 OVERVIEW
TABLE 3 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.2 THREAT OF NEW ENTRANTS
5.5.3 THREAT OF SUBSTITUTES
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 BARGAINING POWER OF BUYERS
5.5.6 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
5.6.1 NORTH AMERICA
5.6.1.1 US
TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.6.1.2 Canada
5.6.2 EUROPE
5.6.3 ASIA PACIFIC
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 South Korea
5.7 REIMBURSEMENT SCENARIO
TABLE 6 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES (2021)
5.8 PRICING TREND ANALYSIS
5.8.1 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY KEY PLAYER, 2021 (USD)
5.8.2 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY REGION/COUNTRY, 2021 (USD)
5.9 PATENT ANALYSIS
FIGURE 18 TOP PATENT APPLICANTS FOR ORTHOPEDIC DEVICES, JANUARY 2012–MARCH 2023
5.10 TRADE ANALYSIS
TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
5.11 ECOSYSTEM MAP
5.12 CASE STUDY ANALYSIS
5.12.1 STENT-ASSISTED COILING (SAC) THERAPY FOR INTRACRANIAL ANEURYSMS
TABLE 9 USAGE OF INTRACRANIAL STENTS FOR TREATMENT OF BROAD-NECKED INTRACRANIAL ANEURYSMS
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 10 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14 STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATION SEGMENTS (%)
5.15 KEY BUYING CRITERIA
FIGURE 21 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES
TABLE 12 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES
6 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY
6.1 INTRODUCTION
TABLE 13 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 14 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 15 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
6.2 CEREBRAL ANEURYSMS
TABLE 16 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 17 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2021–2028 (USD MILLION)
TABLE 18 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY END USER, 2021–2028 (USD MILLION)
6.2.1 EMBOLIC COILS
TABLE 19 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
6.2.1.1 Bare detachable coils
6.2.1.1.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth
TABLE 21 CEREBRAL ANEURYSMS MARKET FOR BARE DETACHABLE COILS, BY REGION, 2021–2028 (USD MILLION)
6.2.1.2 Coated detachable coils
6.2.1.2.1 High cost of coated detachable coils to limit adoption
TABLE 22 CEREBRAL ANEURYSMS MARKET FOR COATED DETACHABLE COILS, BY REGION, 2021–2028 (USD MILLION)
6.2.2 FLOW DIVERSION DEVICES
6.2.2.1 Rising R&D activities to develop novel flow diversion devices to promote growth
TABLE 23 CEREBRAL ANEURYSMS MARKET FOR FLOW DIVERSION DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.2.3 INTRACRANIAL STENTS
6.2.3.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption
TABLE 24 CEREBRAL ANEURYSMS MARKET FOR INTRACRANIAL STENTS, BY REGION, 2021–2028 (USD MILLION)
6.2.4 MICROCATHETERS
6.2.4.1 Growing number of neurovascular procedures and favorable reimbursement scenarios to boost demand
TABLE 25 CEREBRAL ANEURYSMS MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.2.5 GUIDEWIRES
6.2.5.1 Growing utilization of nitinol guidewires for cerebral aneurysm procedures to boost growth
TABLE 26 CEREBRAL ANEURYSMS MARKET FOR GUIDEWIRES, BY REGION, 2021–2028 (USD MILLION)
6.3 ISCHEMIC STROKES
TABLE 27 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE 2021–2028 (USD MILLION)
TABLE 29 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY END USER, 2021–2028 (USD MILLION
6.3.1 CLOT RETRIEVER DEVICES
6.3.1.1 Growing number of clinical trials for development of novel clot retriever stents to drive market
TABLE 30 ISCHEMIC STROKES MARKET FOR CLOT RETRIEVER DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.3.2 SUCTION & ASPIRATION DEVICES
6.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market
TABLE 31 ISCHEMIC STROKES MARKET FOR SUCTION & ASPIRATION DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.3.3 VASCULAR SNARES
6.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares
TABLE 32 ISCHEMIC STROKES MARKET FOR VASCULAR SNARES, BY REGION, 2021–2028 (USD MILLION)
6.3.4 MICROCATHETERS
6.3.4.1 High demand for minimally invasive treatment in ischemic strokes to boost adoption of microcatheters
TABLE 33 ISCHEMIC STROKES MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.3.5 MICROGUIDEWIRES
6.3.5.1 Increasing innovations in guidewires to promote growth
TABLE 34 ISCHEMIC STROKES MARKET FOR MICROGUIDEWIRES, BY REGION, 2021–2028 (USD MILLION)
6.3.6 BALLOON CATHETERS
6.3.6.1 Growing recognition of benefits associated with balloon catheters to bolster demand
TABLE 35 ISCHEMIC STROKES MARKET FOR BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.4 CAROTID ARTERY STENOSIS
TABLE 36 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS CAROTID ARTERY STENOSIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 38 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY END USER, 2021–2028 (USD MILLION)
6.4.1 CAROTID ARTERY STENTS
6.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth
TABLE 39 CAROTID ARTERY STENOSIS MARKET FOR CAROTID ARTERY STENTS, BY REGION, 2021–2028 (USD MILLION)
6.4.2 EMBOLIC PROTECTION DEVICES
6.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth
TABLE 40 CAROTID ARTERY STENOSIS MARKET FOR EMBOLIC PROTECTION DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.4.3 BALLOON CATHETERS
6.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth
TABLE 41 CAROTID ARTERY STENOSIS MARKET FOR BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.5 ARTERIOVENOUS MALFORMATION & FISTULAS
TABLE 42 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY END USER, 2021–2028 (USD MILLION)
6.5.1 LIQUID EMBOLIC AGENTS
6.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth
TABLE 45 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2021–2028 (USD MILLION)
6.5.2 OCCLUSION BALLOON CATHETERS
6.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth
TABLE 46 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR OCCLUSION BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.5.3 MICROCATHETERS
6.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand
TABLE 47 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.6 OTHER DISEASE PATHOLOGIES
TABLE 48 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY END USER, 2021–2028 (USD MILLION)
7 NEUROVASCULAR DEVICES MARKET, BY END USER
7.1 INTRODUCTION
TABLE 50 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
7.2 HOSPITALS AND SURGICAL CENTERS
7.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET
TABLE 51 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021–2028 (USD MILLION)
7.3 AMBULATORY CARE CENTERS
7.3.1 OPERATIONAL AND ECONOMIC BENEFITS OFFERED BY ACCS TO DRIVE MARKET
TABLE 52 NEUROVASCULAR DEVICES MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
7.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
7.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH
TABLE 53 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
8 NEUROVASCULAR DEVICES MARKET, BY REGION
8.1 INTRODUCTION
TABLE 54 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 22 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT
TABLE 55 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 58 NORTH AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2.2 US
8.2.2.1 Presence of established neurovascular device manufacturers to drive market
TABLE 63 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 64 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 65 US: EMBOLIC COILS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 66 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 67 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 68 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.2.3 CANADA
8.2.3.1 Large target pool for ischemic stroke patients to drive market
TABLE 69 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 70 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 71 CANADA: EMBOLIC COILS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 72 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 73 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3 EUROPE
8.3.1 EUROPE: RECESSION IMPACT
TABLE 75 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 77 EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
8.3.2 GERMANY
8.3.2.1 Increasing adoption of endovascular coils and stents to drive market
TABLE 82 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 83 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market
TABLE 88 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.4 UK
8.3.4.1 Rising government initiatives to increase accessibility of neurovascular procedures to drive market
TABLE 94 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 95 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 UK: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.5 ITALY
8.3.5.1 Increasing thrombectomy treatment rates to drive demand for neurovascular devices
TABLE 100 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 101 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 ITALY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 104 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.6 SPAIN
8.3.6.1 Rising number of clinical trials for interventional neurovascular procedures to support market growth
TABLE 106 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 107 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 SPAIN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 109 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 110 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.7 REST OF EUROPE
TABLE 112 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 113 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 REST OF EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 115 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 118 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
FIGURE 23 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT
8.4.2 JAPAN
8.4.2.1 Favorable reimbursement policy for adoption of neurovascular procedures to drive market
TABLE 126 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 127 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 128 JAPAN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.3 CHINA
8.4.3.1 Robust presence of neurovascular device manufacturers to drive market
TABLE 132 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 133 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 CHINA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 136 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.4 INDIA
8.4.4.1 Supportive government initiatives to drive uptake for neurovascular devices
TABLE 138 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 139 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 INDIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.5 AUSTRALIA
8.4.5.1 Rising incidence of cerebrovascular disease to drive market
TABLE 144 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 145 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 AUSTRALIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 147 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.6 SOUTH KOREA
8.4.6.1 Health insurance coverage for neurovascular procedures to support market growth
TABLE 150 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 151 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 SOUTH KOREA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 153 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.7 REST OF ASIA PACIFIC
TABLE 156 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 157 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 REST OF ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 162 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 163 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
8.5.2 BRAZIL
8.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market
TABLE 169 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 170 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 BRAZIL: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 173 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 174 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.5.3 MEXICO
8.5.3.1 Increasing incidence of neurovascular diseases to support market growth
TABLE 175 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 176 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 MEXICO: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 178 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 179 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 180 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.5.4 REST OF LATIN AMERICA
TABLE 181 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 182 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 183 REST OF LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 187 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 188 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 189 MIDDLE EAST & AFRICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 191 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS & FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 193 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 24 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS (2019?2023)
9.2 REVENUE SHARE ANALYSIS
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN NEUROVASCULAR DEVICES MARKET
9.3 MARKET SHARE ANALYSIS
FIGURE 26 NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER (2022)
9.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2022)
9.4.1 STARS
9.4.2 EMERGING LEADERS
9.4.3 PERVASIVE PLAYERS
9.4.4 PARTICIPANTS
FIGURE 27 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2021)
9.5 COMPETITIVE LEADERSHIP MAPPING: STARTUPS/SME EVALUATION QUADRANT (2022)
9.5.1 PROGRESSIVE COMPANIES
9.5.2 RESPONSIVE COMPANIES
9.5.3 DYNAMIC COMPANIES
9.5.4 STARTING BLOCKS
FIGURE 28 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/STARTUPS (2022)
9.6 NEUROVASCULAR DEVICES MARKET: FOOTPRINT ANALYSIS OF LEADING PLAYERS
TABLE 194 COMPANY FOOTPRINT ANALYSIS
TABLE 195 PRODUCT FOOTPRINT
TABLE 196 REGIONAL FOOTPRINT
9.6.1 PRODUCT LAUNCHES & APPROVALS
TABLE 197 NEUROVASCULAR DEVICES MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2019–MARCH 2023)
9.6.2 DEALS
TABLE 198 NEUROVASCULAR DEVICES MARKET: KEY DEALS (JANUARY 2019–MARCH 2023)
9.6.3 OTHER DEVELOPMENTS
TABLE 199 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–MARCH 2023)
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
10.1 KEY PLAYERS
10.1.1 STRYKER
TABLE 200 STRYKER: BUSINESS OVERVIEW
FIGURE 29 STRYKER: COMPANY SNAPSHOT (2022)
10.1.2 MEDTRONIC
TABLE 201 MEDTRONIC: BUSINESS OVERVIEW
FIGURE 30 MEDTRONIC: COMPANY SNAPSHOT (2022)
10.1.3 JOHNSON & JOHNSON
TABLE 202 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
10.1.4 TERUMO CORPORATION
TABLE 203 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 32 TERUMO CORPORATION: COMPANY SNAPSHOT (2021)
10.1.5 PENUMBRA, INC.
TABLE 204 PENUMBRA, INC.: BUSINESS OVERVIEW
FIGURE 33 PENUMBRA, INC.: COMPANY SNAPSHOT (2022)
10.1.6 MICROPORT SCIENTIFIC CORPORATION
TABLE 205 MICROPORT SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 34 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2022)
10.1.7 BALT
TABLE 206 BALT: BUSINESS OVERVIEW
10.1.8 KANEKA CORPORATION
TABLE 207 KANEKA CORPORATION: BUSINESS OVERVIEW
FIGURE 35 KANEKA CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 208 PRODUCT LAUNCHES
10.1.9 PHENOX GMBH
TABLE 209 PHENOX GMBH: BUSINESS OVERVIEW
10.1.10 ASAHI INTECC CO., LTD
TABLE 210 ASAHI INTECC CO., LTD.: BUSINESS OVERVIEW
FIGURE 36 ASAHI INTECC: COMPANY SNAPSHOT (2022)
10.1.11 PERFLOW MEDICAL LTD.
TABLE 211 PERFLOW MEDICAL LTD.: BUSINESS OVERVIEW
10.1.12 RAPID MEDICAL
TABLE 212 RAPID MEDICAL: BUSINESS OVERVIEW
10.1.13 CERUS ENDOVASCULAR INC.
TABLE 213 CERUS ENDOVASCULAR INC.: BUSINESS OVERVIEW
10.1.14 ACANDIS GMBH
TABLE 214 ACANDIS GMBH: BUSINESS OVERVIEW
TABLE 215 ACANDIS GMBH: PRODUCTS OFFERED
10.1.15 EVASC
TABLE 216 EVASC: BUSINESS OVERVIEW
10.1.16 SENSOME
TABLE 217 SENSOME: BUSINESS OVERVIEW
10.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
TABLE 218 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: BUSINESS OVERVIEW
FIGURE 37 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: COMPANY SNAPSHOT (2021)
10.1.18 IMPERATIVE CARE
TABLE 219 IMPERATIVE CARE: BUSINESS OVERVIEW
TABLE 220 IMPERATIVE CARE: PRODUCT LAUNCHES AND APPROVALS
10.1.19 MEDIKIT CO., LTD.
TABLE 221 MEDIKIT CO., LTD.: BUSINESS OVERVIEW
10.1.20 ZYLOX-TONBRIDGE MEDICAL CO., LTD.
TABLE 222 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 38 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: COMPANY SNAPSHOT (2021)
TABLE 223 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: PRODUCT LAUNCHES AND APPROVALS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS
10.2.1 SILK ROAD MEDICAL, INC.
10.2.2 ARTIO MEDICAL, INC.
10.2.3 IVASCULAR
10.2.4 OXFORDENDOVASCULAR
10.2.5 NEUROVASC TECHNOLOGIES, INC.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 MARKET STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 NEUROVASCULAR DEVICES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 PRODUCT-BASED MARKET ESTIMATION
2.2.2 VOLUME-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: NEUROVASCULAR DEVICES MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
2.4.1 RESEARCH ASSUMPTIONS
2.4.2 RESEARCH LIMITATIONS
2.5 RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 7 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 8 HOSPITALS AND SURGICAL CENTERS SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD
4 PREMIUM INSIGHTS
4.1 NEUROVASCULAR DEVICES MARKET OVERVIEW
FIGURE 10 AN INCREASE IN THE NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS BRAIN/ CEREBRAL ANEURYSMS, STROKES, AND EPILEPSY, IS EXPECTED TO DRIVE THE MARKET GROWTH.
4.2 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 11 CEREBRAL ANEURYSMS TO DOMINATE NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD
4.3 NEUROVASCULAR DEVICES MARKET, BY REGION AND DISEASE PATHOLOGY (2022)
FIGURE 12 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE IN US
4.4 NEUROVASCULAR DEVICES MARKET, BY COUNTRY
FIGURE 13 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 14 NEUROVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of neurovascular diseases
FIGURE 15 PROPORTION OF GERIATRIC TO TOTAL WORLD POPULATION, BY COUNTRY, 2020 VS. 2030 (MILLION PEOPLE)
5.2.1.2 Availability of medical reimbursements for neurovascular procedures
TABLE 2 US: REIMBURSEMENT FOR INTERVENTIONAL NEUROLOGY PROCEDURES
5.2.1.3 Expansion of healthcare infrastructure across emerging economies
5.2.1.4 Rising demand for effective neurovascular therapies
5.2.2 RESTRAINTS
5.2.2.1 Shortage of skilled neurosurgeons
5.2.2.2 High procedural cost of neurovascular surgeries and associated products
5.2.3 OPPORTUNITIES
5.2.3.1 Rising R&D activities for neurovascular therapies
5.2.3.2 Growing preference for minimally invasive neurosurgical procedures
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory approval process for medical devices
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED THROUGH REGULATION & DISTRIBUTION STAGES
5.5 PORTER’S FIVE FORCES ANALYSIS
5.5.1 OVERVIEW
TABLE 3 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.2 THREAT OF NEW ENTRANTS
5.5.3 THREAT OF SUBSTITUTES
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 BARGAINING POWER OF BUYERS
5.5.6 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
5.6.1 NORTH AMERICA
5.6.1.1 US
TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.6.1.2 Canada
5.6.2 EUROPE
5.6.3 ASIA PACIFIC
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 South Korea
5.7 REIMBURSEMENT SCENARIO
TABLE 6 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES (2021)
5.8 PRICING TREND ANALYSIS
5.8.1 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY KEY PLAYER, 2021 (USD)
5.8.2 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY REGION/COUNTRY, 2021 (USD)
5.9 PATENT ANALYSIS
FIGURE 18 TOP PATENT APPLICANTS FOR ORTHOPEDIC DEVICES, JANUARY 2012–MARCH 2023
5.10 TRADE ANALYSIS
TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)
5.11 ECOSYSTEM MAP
5.12 CASE STUDY ANALYSIS
5.12.1 STENT-ASSISTED COILING (SAC) THERAPY FOR INTRACRANIAL ANEURYSMS
TABLE 9 USAGE OF INTRACRANIAL STENTS FOR TREATMENT OF BROAD-NECKED INTRACRANIAL ANEURYSMS
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 10 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14 STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATION SEGMENTS (%)
5.15 KEY BUYING CRITERIA
FIGURE 21 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES
TABLE 12 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES
6 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY
6.1 INTRODUCTION
TABLE 13 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 14 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 15 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
6.2 CEREBRAL ANEURYSMS
TABLE 16 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 17 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2021–2028 (USD MILLION)
TABLE 18 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY END USER, 2021–2028 (USD MILLION)
6.2.1 EMBOLIC COILS
TABLE 19 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
6.2.1.1 Bare detachable coils
6.2.1.1.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth
TABLE 21 CEREBRAL ANEURYSMS MARKET FOR BARE DETACHABLE COILS, BY REGION, 2021–2028 (USD MILLION)
6.2.1.2 Coated detachable coils
6.2.1.2.1 High cost of coated detachable coils to limit adoption
TABLE 22 CEREBRAL ANEURYSMS MARKET FOR COATED DETACHABLE COILS, BY REGION, 2021–2028 (USD MILLION)
6.2.2 FLOW DIVERSION DEVICES
6.2.2.1 Rising R&D activities to develop novel flow diversion devices to promote growth
TABLE 23 CEREBRAL ANEURYSMS MARKET FOR FLOW DIVERSION DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.2.3 INTRACRANIAL STENTS
6.2.3.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption
TABLE 24 CEREBRAL ANEURYSMS MARKET FOR INTRACRANIAL STENTS, BY REGION, 2021–2028 (USD MILLION)
6.2.4 MICROCATHETERS
6.2.4.1 Growing number of neurovascular procedures and favorable reimbursement scenarios to boost demand
TABLE 25 CEREBRAL ANEURYSMS MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.2.5 GUIDEWIRES
6.2.5.1 Growing utilization of nitinol guidewires for cerebral aneurysm procedures to boost growth
TABLE 26 CEREBRAL ANEURYSMS MARKET FOR GUIDEWIRES, BY REGION, 2021–2028 (USD MILLION)
6.3 ISCHEMIC STROKES
TABLE 27 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE 2021–2028 (USD MILLION)
TABLE 29 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY END USER, 2021–2028 (USD MILLION
6.3.1 CLOT RETRIEVER DEVICES
6.3.1.1 Growing number of clinical trials for development of novel clot retriever stents to drive market
TABLE 30 ISCHEMIC STROKES MARKET FOR CLOT RETRIEVER DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.3.2 SUCTION & ASPIRATION DEVICES
6.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market
TABLE 31 ISCHEMIC STROKES MARKET FOR SUCTION & ASPIRATION DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.3.3 VASCULAR SNARES
6.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares
TABLE 32 ISCHEMIC STROKES MARKET FOR VASCULAR SNARES, BY REGION, 2021–2028 (USD MILLION)
6.3.4 MICROCATHETERS
6.3.4.1 High demand for minimally invasive treatment in ischemic strokes to boost adoption of microcatheters
TABLE 33 ISCHEMIC STROKES MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.3.5 MICROGUIDEWIRES
6.3.5.1 Increasing innovations in guidewires to promote growth
TABLE 34 ISCHEMIC STROKES MARKET FOR MICROGUIDEWIRES, BY REGION, 2021–2028 (USD MILLION)
6.3.6 BALLOON CATHETERS
6.3.6.1 Growing recognition of benefits associated with balloon catheters to bolster demand
TABLE 35 ISCHEMIC STROKES MARKET FOR BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.4 CAROTID ARTERY STENOSIS
TABLE 36 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS CAROTID ARTERY STENOSIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 37 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 38 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY END USER, 2021–2028 (USD MILLION)
6.4.1 CAROTID ARTERY STENTS
6.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth
TABLE 39 CAROTID ARTERY STENOSIS MARKET FOR CAROTID ARTERY STENTS, BY REGION, 2021–2028 (USD MILLION)
6.4.2 EMBOLIC PROTECTION DEVICES
6.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth
TABLE 40 CAROTID ARTERY STENOSIS MARKET FOR EMBOLIC PROTECTION DEVICES, BY REGION, 2021–2028 (USD MILLION)
6.4.3 BALLOON CATHETERS
6.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth
TABLE 41 CAROTID ARTERY STENOSIS MARKET FOR BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.5 ARTERIOVENOUS MALFORMATION & FISTULAS
TABLE 42 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY END USER, 2021–2028 (USD MILLION)
6.5.1 LIQUID EMBOLIC AGENTS
6.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth
TABLE 45 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2021–2028 (USD MILLION)
6.5.2 OCCLUSION BALLOON CATHETERS
6.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth
TABLE 46 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR OCCLUSION BALLOON CATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.5.3 MICROCATHETERS
6.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand
TABLE 47 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR MICROCATHETERS, BY REGION, 2021–2028 (USD MILLION)
6.6 OTHER DISEASE PATHOLOGIES
TABLE 48 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY END USER, 2021–2028 (USD MILLION)
7 NEUROVASCULAR DEVICES MARKET, BY END USER
7.1 INTRODUCTION
TABLE 50 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
7.2 HOSPITALS AND SURGICAL CENTERS
7.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET
TABLE 51 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021–2028 (USD MILLION)
7.3 AMBULATORY CARE CENTERS
7.3.1 OPERATIONAL AND ECONOMIC BENEFITS OFFERED BY ACCS TO DRIVE MARKET
TABLE 52 NEUROVASCULAR DEVICES MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
7.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
7.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH
TABLE 53 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
8 NEUROVASCULAR DEVICES MARKET, BY REGION
8.1 INTRODUCTION
TABLE 54 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 22 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT
TABLE 55 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 58 NORTH AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 59 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 62 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2.2 US
8.2.2.1 Presence of established neurovascular device manufacturers to drive market
TABLE 63 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 64 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 65 US: EMBOLIC COILS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 66 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 67 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 68 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.2.3 CANADA
8.2.3.1 Large target pool for ischemic stroke patients to drive market
TABLE 69 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 70 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 71 CANADA: EMBOLIC COILS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 72 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 73 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3 EUROPE
8.3.1 EUROPE: RECESSION IMPACT
TABLE 75 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 77 EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
8.3.2 GERMANY
8.3.2.1 Increasing adoption of endovascular coils and stents to drive market
TABLE 82 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 83 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market
TABLE 88 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.4 UK
8.3.4.1 Rising government initiatives to increase accessibility of neurovascular procedures to drive market
TABLE 94 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 95 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 UK: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.5 ITALY
8.3.5.1 Increasing thrombectomy treatment rates to drive demand for neurovascular devices
TABLE 100 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 101 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 ITALY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 104 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.6 SPAIN
8.3.6.1 Rising number of clinical trials for interventional neurovascular procedures to support market growth
TABLE 106 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 107 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 SPAIN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 109 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 110 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.3.7 REST OF EUROPE
TABLE 112 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 113 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 REST OF EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 115 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 118 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
FIGURE 23 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT
8.4.2 JAPAN
8.4.2.1 Favorable reimbursement policy for adoption of neurovascular procedures to drive market
TABLE 126 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 127 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 128 JAPAN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.3 CHINA
8.4.3.1 Robust presence of neurovascular device manufacturers to drive market
TABLE 132 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 133 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 CHINA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 136 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.4 INDIA
8.4.4.1 Supportive government initiatives to drive uptake for neurovascular devices
TABLE 138 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 139 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 140 INDIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.5 AUSTRALIA
8.4.5.1 Rising incidence of cerebrovascular disease to drive market
TABLE 144 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 145 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 AUSTRALIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 147 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.6 SOUTH KOREA
8.4.6.1 Health insurance coverage for neurovascular procedures to support market growth
TABLE 150 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 151 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 SOUTH KOREA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 153 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 155 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.4.7 REST OF ASIA PACIFIC
TABLE 156 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 157 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 REST OF ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 160 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 162 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 163 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 165 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
8.5.2 BRAZIL
8.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market
TABLE 169 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 170 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 BRAZIL: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 172 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 173 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 174 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.5.3 MEXICO
8.5.3.1 Increasing incidence of neurovascular diseases to support market growth
TABLE 175 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 176 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 MEXICO: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 178 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 179 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 180 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.5.4 REST OF LATIN AMERICA
TABLE 181 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 182 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 183 REST OF LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 184 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 185 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 186 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 187 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 188 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021–2028 (USD MILLION)
TABLE 189 MIDDLE EAST & AFRICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 190 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 191 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS & FISTULAS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 193 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 24 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS (2019?2023)
9.2 REVENUE SHARE ANALYSIS
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN NEUROVASCULAR DEVICES MARKET
9.3 MARKET SHARE ANALYSIS
FIGURE 26 NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER (2022)
9.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2022)
9.4.1 STARS
9.4.2 EMERGING LEADERS
9.4.3 PERVASIVE PLAYERS
9.4.4 PARTICIPANTS
FIGURE 27 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2021)
9.5 COMPETITIVE LEADERSHIP MAPPING: STARTUPS/SME EVALUATION QUADRANT (2022)
9.5.1 PROGRESSIVE COMPANIES
9.5.2 RESPONSIVE COMPANIES
9.5.3 DYNAMIC COMPANIES
9.5.4 STARTING BLOCKS
FIGURE 28 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/STARTUPS (2022)
9.6 NEUROVASCULAR DEVICES MARKET: FOOTPRINT ANALYSIS OF LEADING PLAYERS
TABLE 194 COMPANY FOOTPRINT ANALYSIS
TABLE 195 PRODUCT FOOTPRINT
TABLE 196 REGIONAL FOOTPRINT
9.6.1 PRODUCT LAUNCHES & APPROVALS
TABLE 197 NEUROVASCULAR DEVICES MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2019–MARCH 2023)
9.6.2 DEALS
TABLE 198 NEUROVASCULAR DEVICES MARKET: KEY DEALS (JANUARY 2019–MARCH 2023)
9.6.3 OTHER DEVELOPMENTS
TABLE 199 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS (JANUARY 2019–MARCH 2023)
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
10.1 KEY PLAYERS
10.1.1 STRYKER
TABLE 200 STRYKER: BUSINESS OVERVIEW
FIGURE 29 STRYKER: COMPANY SNAPSHOT (2022)
10.1.2 MEDTRONIC
TABLE 201 MEDTRONIC: BUSINESS OVERVIEW
FIGURE 30 MEDTRONIC: COMPANY SNAPSHOT (2022)
10.1.3 JOHNSON & JOHNSON
TABLE 202 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
10.1.4 TERUMO CORPORATION
TABLE 203 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 32 TERUMO CORPORATION: COMPANY SNAPSHOT (2021)
10.1.5 PENUMBRA, INC.
TABLE 204 PENUMBRA, INC.: BUSINESS OVERVIEW
FIGURE 33 PENUMBRA, INC.: COMPANY SNAPSHOT (2022)
10.1.6 MICROPORT SCIENTIFIC CORPORATION
TABLE 205 MICROPORT SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 34 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2022)
10.1.7 BALT
TABLE 206 BALT: BUSINESS OVERVIEW
10.1.8 KANEKA CORPORATION
TABLE 207 KANEKA CORPORATION: BUSINESS OVERVIEW
FIGURE 35 KANEKA CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 208 PRODUCT LAUNCHES
10.1.9 PHENOX GMBH
TABLE 209 PHENOX GMBH: BUSINESS OVERVIEW
10.1.10 ASAHI INTECC CO., LTD
TABLE 210 ASAHI INTECC CO., LTD.: BUSINESS OVERVIEW
FIGURE 36 ASAHI INTECC: COMPANY SNAPSHOT (2022)
10.1.11 PERFLOW MEDICAL LTD.
TABLE 211 PERFLOW MEDICAL LTD.: BUSINESS OVERVIEW
10.1.12 RAPID MEDICAL
TABLE 212 RAPID MEDICAL: BUSINESS OVERVIEW
10.1.13 CERUS ENDOVASCULAR INC.
TABLE 213 CERUS ENDOVASCULAR INC.: BUSINESS OVERVIEW
10.1.14 ACANDIS GMBH
TABLE 214 ACANDIS GMBH: BUSINESS OVERVIEW
TABLE 215 ACANDIS GMBH: PRODUCTS OFFERED
10.1.15 EVASC
TABLE 216 EVASC: BUSINESS OVERVIEW
10.1.16 SENSOME
TABLE 217 SENSOME: BUSINESS OVERVIEW
10.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
TABLE 218 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: BUSINESS OVERVIEW
FIGURE 37 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: COMPANY SNAPSHOT (2021)
10.1.18 IMPERATIVE CARE
TABLE 219 IMPERATIVE CARE: BUSINESS OVERVIEW
TABLE 220 IMPERATIVE CARE: PRODUCT LAUNCHES AND APPROVALS
10.1.19 MEDIKIT CO., LTD.
TABLE 221 MEDIKIT CO., LTD.: BUSINESS OVERVIEW
10.1.20 ZYLOX-TONBRIDGE MEDICAL CO., LTD.
TABLE 222 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 38 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: COMPANY SNAPSHOT (2021)
TABLE 223 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: PRODUCT LAUNCHES AND APPROVALS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS
10.2.1 SILK ROAD MEDICAL, INC.
10.2.2 ARTIO MEDICAL, INC.
10.2.3 IVASCULAR
10.2.4 OXFORDENDOVASCULAR
10.2.5 NEUROVASC TECHNOLOGIES, INC.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
